Chiusura precedente | 0,4500 |
Aperto | 0,4500 |
Denaro | 0,2000 |
Domanda | 1,1500 |
Prezzo d'esercizio | 20,00 |
Scadenza | 2025-03-21 |
Min-Max giorno | 0,4500 - 0,4500 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 5 |
SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25, at 7:00 a.m. PT / 10:00 a.m. ET. A live webcast of the fireside chat can be accessed under Events & Presentations in the Investors section of the
SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include seven poster presentations, one of which is a late-breaking poster, and on
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on November 2, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section